FyMed, Inc.

Press Releases
immunomodulatory

FyMed Announces Notice of Allowance for US Patent Covering Fy10 Technology Platform

FyMed Inc., a specialty pharmaceutical company focused on the development and commercialization of novel therapeutics announced that its application covering the Fy10 technology platform was allowed for issuance as a new patent by the USPTO. Read More...

Early Release: FyMed Gets Patent for Novel Immunomodulatory Drug

Pharmaceutical firm FyMed Inc. has received a patent for a novel immunomodulatory drug used in the treatment of autoimmune diseases.
Read More...